Dr. Gordon B. Mills from the University of Texas MD Anderson Cancer Center Discusses the Field of Targeted Therapeutics
Gordon B. Mills, MD, PhD, chairman, Department of Systems Biology, chief, Section of Molecular Therapeutics, Professor of Medicine and Immunology at the University of Texas MD Anderson Cancer Center, explains that the field of targeted therapeutics was initially heralded as a "magic bullet" against cancer.
The ultimate paradigm at the onset of targeted therapy was the use of imatinib (Gleevec) for chronic myeloid leukemia (CML). This therapy incurred an incredible response in patients and the idea in place at the time was that this would be the standard for future targeted therapies.
Unfortunately this paradigm has not been realized in all cases of target therapies. Mills mentions that almost all other new agents are restricted to a subpopulation of patients and from those with the correct marker only a few will transiently respond.
This disappointment is the direct result of two mechanisms: